Pre-made Ginisortamab benchmark antibody ( Whole mAb, anti-GREM1/Gremlin-1 therapeutic antibody, Anti-C15DUPq/CKTSF1B1/CRAC1/CRCS4/DAND2/DRM/DUP15q/GREMLIN/HMPS/HMPS1/IHG-2/MPSH/PIG2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ginisortamab biosimilar, Whole mAb, Anti-GREM1/Gremlin-1 Antibody: Anti-C15DUPq/CKTSF1B1/CRAC1/CRCS4/DAND2/DRM/DUP15q/GREMLIN/HMPS/HMPS1/IHG-2/MPSH/PIG2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-669-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Ginisortamab biosimilar, Whole mAb, Anti-GREM1/Gremlin-1 Antibody: Anti-C15DUPq/CKTSF1B1/CRAC1/CRCS4/DAND2/DRM/DUP15q/GREMLIN/HMPS/HMPS1/IHG-2/MPSH/PIG2 therapeutic antibody
INN Name	Ginisortamab
Target	Gremlin-1
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2021
Year Recommended	na
Companies	UCB
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na